# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pierre Le Moyne d'Iberville (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET014-SYN-TD
- Date: 1705-10-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marguerite Delacroix-Boateng, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Pre-departure review before a naval deployment to French Guiana and the French Antilles. **S**

## History of present illness

Mr. Le Moyne d'Iberville returns about three months before the squadron sails. He had a sore arm for a day after the vaccines and nothing else. He has had no fever since his malaria treatment seven months ago. He will be aboard ship for the crossing and in the islands, then ashore near Cayenne and Kourou, possibly with river work inland where malaria is transmitted. He will be responsible for the health measures of his crews and wants to set the example. He asked what he should carry. **S**

| Element | Detail |
|---|---|
| Vaccine reactions | Sore arm for a day |
| Malaria | No fever in seven months |
| Itinerary | Sea crossing, the Antilles, then French Guiana with possible inland river work |
| Question | What to carry and how to protect his crews |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight loss |
| Gastrointestinal | Negative | No diarrhea |
| Psychiatric | Negative | Busy but well |

3 systems reviewed. **S**

## Current medications

- Atovaquone-proguanil 250 mg/100 mg tablet: one tablet daily with food, starting one to two days before entering a malaria area, daily there, and for seven days after leaving **S**
- Azithromycin 500 mg tablet: one tablet daily for up to three days for severe travelers' diarrhea (standby supply) **S**
- Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) daily with food for 14 days, starting when he leaves the malaria areas (terminal prophylaxis) **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 64 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 69.2 kg; BMI 22.6 kg/m². All vital signs are synthetic.

Hemoglobin: 14.1 g/dL; Platelets: 236 10*3/uL. All results are synthetic.

## Change since baseline

- Hemoglobin: 13 g/dL (low) at baseline, 14.1 g/dL at this visit **S**
- Platelets: 141 10*3/uL (low) at baseline, 236 10*3/uL at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**
- Influenza vaccine, inactivated, trivalent, preservative-free **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; temperature 36.6 C, blood pressure 122/76, pulse 64, weight 69.2 kg |
| Abdomen | Spleen not palpable |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pre-travel care for the deployment** (Z71.84). Vaccines complete for departure: the yellow fever certificate is valid, and hepatitis B dose 2 and influenza vaccine are given today. Malaria is transmitted in parts of French Guiana, where P. vivax is most common, followed by P. falciparum, with chloroquine resistance; CDC lists atovaquone-proguanil, doxycycline, mefloquine and tafenoquine. Atovaquone-proguanil is chosen because it is taken only from one to two days before to seven days after the malaria areas. After months in a P. vivax area, primaquine terminal prophylaxis is advised, and his G6PD is normal. Dengue and chikungunya are spread by day-biting mosquitoes and typhus by fleas, lice and mites, so vector avoidance is the main protection. Pre-departure blood count normal: hemoglobin 14.1 g/dL, platelets 236 x10^3/uL. **S**
   - Atovaquone-proguanil one tablet daily with food, from one to two days before entering a malaria area until seven days after leaving.
   - Primaquine 30 mg base daily for 14 days, starting when he leaves the malaria areas.
   - EPA-registered repellent on skin, permethrin-treated clothing and bed nets, screened or air-conditioned quarters; long sleeves at dawn and dusk; flea and lice control aboard and clean bedding.
   - Food and water: safe water, well-cooked food, washing hands; azithromycin 500 mg daily for up to three days for severe diarrhea or diarrhea with fever or blood, with oral rehydration.
   - Any fever during travel or in the months after return means a malaria test the same day; tell the doctor about the travel.
   - Carry the medical summary, the yellow fever certificate, and all medicines in their original packs.
2. **Relapsing P. vivax malaria, after radical cure** (B51.9). No relapse seven months after radical cure. **S**
   - Continue the fever action plan; the terminal primaquine course also covers any new P. vivax exposure.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Relapse surveillance and the fever action plan | Every visit | Completed today | No fever in seven months; plan extended to travel and after return |
| Laboratory | Pre-departure blood count | Once, before a long deployment | Completed today | Hemoglobin 14.1 g/dL, platelets 236 x10^3/uL |
| Medication safety | Malaria chemoprophylaxis choice, dosing and interactions | Before travel | Completed today | Atovaquone-proguanil prescribed; no interacting medicines; take with food |
| Medication safety | Terminal prophylaxis (presumptive antirelapse therapy) for prolonged P. vivax exposure | After leaving the malaria areas | Completed today | Primaquine 30 mg base daily for 14 days prescribed, G6PD normal |
| Examination | Yellow fever certificate valid on arrival | Before travel | Up to date | Vaccinated eleven weeks ago; certificate valid |
| Examination | Hepatitis B vaccine series | Two doses one month apart | Completed today | HepB-CpG dose 2 today |
| Examination | Hepatitis A vaccine dose 2 | Six to twelve months after dose 1 | Due | Due after the deployment; dose 1 gives protection for the trip |
| Examination | Influenza vaccine | Each season | Completed today | Given today |
| Self-management | Vector avoidance for dengue, chikungunya and typhus | Before and during travel | Completed today | Repellent, permethrin-treated clothing, nets, screens; flea and lice control aboard; no dengue vaccine is recommended for travelers |
| Examination | Chikungunya vaccine | Before travel, if an outbreak notice applies | Due | CDC lists a chikungunya outbreak in French Guiana and recommends vaccination for travelers to outbreak areas; to be decided at a short visit a month before departure against the notice then current |
| Self-management | Food and water precautions and travelers' diarrhea self-treatment | Before travel | Completed today | Advice given; standby azithromycin prescribed |

## Goal progress

- No further malaria relapse in the six months after radical cure. Outcome by 1705-10-13: No fever in the seven months since finishing primaquine. **S**
- All required and recommended travel vaccines given, with a valid yellow fever certificate, at least ten days before departure. Outcome by 1705-10-13: Yellow fever, hepatitis A dose 1, hepatitis B two-dose series, typhoid and influenza vaccines given; certificate valid. **S**
- Knows to have a malaria test the same day for any fever, during travel and for months after return. Outcome by 1705-03-31: Carries a fever card and explained the plan back correctly. **S**

## Medication changes

- Started: Atovaquone-proguanil 250 mg/100 mg tablet: one tablet daily with food, starting one to two days before entering a malaria area, daily there, and for seven days after leaving **S**
- Started: Azithromycin 500 mg tablet: one tablet daily for up to three days for severe travelers' diarrhea (standby supply) **S**
- Started: Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) daily with food for 14 days, starting when he leaves the malaria areas (terminal prophylaxis) **S**

## Guideline basis

- CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026), Centers for Disease Control and Prevention
- CDC Yellow Book: Health Information for International Travel, 2026 edition. Yellow Fever (2026), Centers for Disease Control and Prevention
- French Guiana (France): travel health destination page (yellow fever and malaria information updated April 2025) (2026), Centers for Disease Control and Prevention
- CDC Yellow Book: Health Information for International Travel, 2026 edition. Dengue (2026), Centers for Disease Control and Prevention
- CDC Yellow Book: Health Information for International Travel, 2026 edition. Rickettsial Diseases (2026), Centers for Disease Control and Prevention
- CDC Yellow Book: Health Information for International Travel, 2026 edition. Travelers' Diarrhea (2026), Centers for Disease Control and Prevention
- The practice of travel medicine: guidelines by the Infectious Diseases Society of America (Hill DR, et al. Clin Infect Dis 2006;43(12):1499-1539) (2006), Infectious Diseases Society of America

## Follow-up

- Short visit a month before departure for the chikungunya vaccine decision. Post-travel visit on return, sooner for any fever. **S**

